Financial Review: Alder BioPharmaceuticals (ALDR) & Its Peers

Alder BioPharmaceuticals (NASDAQ: ALDR) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Alder BioPharmaceuticals to related businesses based on the strength of its dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Risk and Volatility

Alder BioPharmaceuticals has a beta of 2.48, meaning that its stock price is 148% more volatile than the S&P 500. Comparatively, Alder BioPharmaceuticals’ peers have a beta of 8.00, meaning that their average stock price is 700% more volatile than the S&P 500.

Profitability

This table compares Alder BioPharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alder BioPharmaceuticals N/A -93.14% -84.14%
Alder BioPharmaceuticals Competitors -5,311.45% -433.95% -39.53%

Institutional and Insider Ownership

96.9% of Alder BioPharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 10.6% of Alder BioPharmaceuticals shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Alder BioPharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Alder BioPharmaceuticals $110,000.00 -$156.25 million -2.04
Alder BioPharmaceuticals Competitors $284.28 million $34.29 million 79.62

Alder BioPharmaceuticals’ peers have higher revenue and earnings than Alder BioPharmaceuticals. Alder BioPharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for Alder BioPharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alder BioPharmaceuticals 0 1 11 0 2.92
Alder BioPharmaceuticals Competitors 852 3199 11603 231 2.71

Alder BioPharmaceuticals presently has a consensus target price of $30.58, indicating a potential upside of 179.30%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.91%. Given Alder BioPharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Alder BioPharmaceuticals is more favorable than its peers.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply